Blurbs

Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and Intellia Therapeutics (NTLA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocular Therapeutix (OCULResearch Report) and Intellia Therapeutics (NTLAResearch Report) with bullish sentiments.

Ocular Therapeutix (OCUL)

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Ocular Therapeutix, with a price target of $22.00. The company’s shares closed last Monday at $5.58, close to its 52-week low of $4.71.

According to TipRanks.com, Wolleben is ranked 0 out of 5 stars with an average return of -17.5% and a 27.8% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.

Ocular Therapeutix has an analyst consensus of Strong Buy, with a price target consensus of $18.00.

See today’s best-performing stocks on TipRanks >>

Intellia Therapeutics (NTLA)

JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Intellia Therapeutics today and set a price target of $165.00. The company’s shares closed last Monday at $98.85.

According to TipRanks.com, Tuerkcan is a 3-star analyst with an average return of 6.4% and a 36.0% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Crispr Therapeutics AG, and Logicbio Therapeutics.

Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $155.64, which is a 60.2% upside from current levels. In a report issued on February 18, William Blair also initiated coverage with a Buy rating on the stock with a $144.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OCUL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos